CDMO
PolTREG offers development, manufacturing, and testing services, along with tools to support clients through all stages of therapy development, from research to commercialization.
poltreg.bioCrawled Nov 9, 2026
PolTREG offers development, manufacturing, and testing services, along with tools to support clients through all stages of therapy development, from research to commercialization.
The trial is a randomized, placebo-controlled, double-blind trial. Participants are randomly assigned to one of four groups – they receive:
There are up to 100 diseases that are in this group, and most of them are chronic diseases with worsening complications over time. These are currently incurable diseases, and available treatments are often only able to delay the progression of the disease. The Company’s TREGs and TREGs combination therapies under development aim to halt progress of these diseases in the pre-symptomatic or early stages, and to improve the quality of life for patients with more advanced disease.
The cells are not subjected to genetic manipulation, only the number of cells – naturally low or with lower activity in patients with type 1 diabetes – is multiplied under laboratory conditions, before being transfused back to the patient.
Scientists from Poltreg published report describing long-term effects of the therapy. The report proves that the patients treated with TREG cells could produce insulin more than 2 years after administration of the preparation.
Inventor of TREG method Prof. Piotr Trzonkowski has received the Foundation for Polish Science Prize 2017 in the life and earth sciences for studies on regulatory T cells and their pioneering use in cell therapy of human diseases. This is the most important scientific prize in Poland. More:
Last patient recruited into phase I trial on multiple sclerosis in STRATEGMED TREGS programme. Full results of the study will be available in second quarter of 2019.
Scientists from Poltreg participated in the final meeting of the AFACTT research network, which unites around 100 scientists from 20 European universities to advance cell-based tolerance-inducing therapies.
Scientists from Poltreg published report with new data on laboratory technique increasing stability and quality of TREG preparation used in the treatment. The method is a subject of new patent application.
Last patient recruited into phase II trial on type 1 diabetes in STRATEGMED TREGS programme. Full results of the study will be available in third quarter of 2019.
Scientists from the Medical University of Gdańsk, Poltreg S.A., and Technische Universität Dresden published a study in *Cytotherapy* describing a new generation of medicinal products containing antigen-specific T regulatory cells.
Doctor Mateusz Gliwiński received the GOLDEN OTIS 2021 award for his PhD work proving proinsulin’s role in type 1 diabetes and proposing a new cellular therapy based on this antigen.
The Czech Liaison Office for Research, Development and Innovation highlighted PolTREG’s project as an example of good practice supported by Horizon 2020.
The Ministry of Regional Development just released results of the competition 2.1 PO IR (Support for R@D center). Poltreg S.A. has been scored the highest 28 points and received grant = 10 597 978,30 PLN (≈2.4mln Euro) for the infrastructure.
Participation in the preparation of laboratory documentation.
PolTREG S.A. is conducting a price inquiry to select a service provider for maintaining scientific and research equipment used in a cell therapy project for prediabetes.
PolTREG S.A. conducts market research to select a supplier of recombinant interleukin 2 for a prediabetes cell therapy project, co-financed by the Medical Research Agency.
PolTREG’s four most advanced projects are already in the clinical stage of development in the areas of type 1 diabetes and multiple sclerosis. The portfolio also includes projects based on the next generation of genetically modified T-regulatory lymphocytes.
PolTREG applies its expertise to address societal, economic, and environmental challenges, focusing on improving patient and family quality of life through medical advancements.
PTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis
Information clause on the processing of personal data of persons contacting Poltreg S.A.